Donate to Science & Enterprise

S&E on Mastodon

S&E on LinkedIn

S&E on Flipboard

Please share Science & Enterprise

Cancer Immunotherapy Biotech Issues $80M IPO

Wall Street sign

A biotechnology company designing immunotherapies for solid tumor cancers with a patient’s white blood cells is raising $80 million in its initial public offering or IPO. . . . → Read More: Cancer Immunotherapy Biotech Issues $80M IPO

Gut-Brain Meds Developer Going Public in Merger

Milk splashing

(Myriams-Fotos, Pixabay. https://pixabay.com/photos/milk-splash-drops-food-liquid-4755234/)

31 Oct. 2022. A developer of synthetic biology treatments for inflammatory and neurological disorders linked to the gut is becoming a public company through a special acquisition merger. Intrinsic Medicine Inc. in Seattle is joining with Phoenix Biotech Acquisition Corp. in Oakland, California, a special purpose acquisition company or SPAC, . . . → Read More: Gut-Brain Meds Developer Going Public in Merger

Digital Mental Therapy Company to Go Public in Merger

Child with computer tablet

A creator of game therapies for cognitive impairments is becoming a publicly-traded company through a special purpose acquisition company or SPAC. . . . → Read More: Digital Mental Therapy Company to Go Public in Merger

Synthetic Antibody Company Goes Public in $230M Merger

Four fist bump

A developer of synthetic antibodies for inflammatory and skin disorders is becoming a public company through a special purpose acquisition-merger. . . . → Read More: Synthetic Antibody Company Goes Public in $230M Merger

RNA Manufacturer Goes Public in $282M Merger

Bumble bee and flower

A company producing synthetic RNA for agricultural and biomedical applications is now a public company after a special-purpose acquisition. . . . → Read More: RNA Manufacturer Goes Public in $282M Merger

Synthetic Bio Company Goes Public in $2.5B Merger

Investment graphic

A company developing synthetic biology and engineering tools for biotechnology is becoming a public company through a special-purpose acquisition. . . . → Read More: Synthetic Bio Company Goes Public in $2.5B Merger

Biomanufacturing Materials Company Issues $500M IPO

Wall Street sign

Zymergen Inc., a developer of materials made with synthetic biology for industrial products is raising $500 million in its initial public stock offering. . . . → Read More: Biomanufacturing Materials Company Issues $500M IPO

Engineered Cell Therapy Company Issues $588M IPO

NASDAQ share price display

A company developing regenerative therapies with engineered stem cells for cancer and other diseases is raising $587.5 million in its initial public offering or IPO. . . . → Read More: Engineered Cell Therapy Company Issues $588M IPO

2020 Venture Funds Mixed, Biotech Keeps Sizzling

2020 venture transactions

Total venture investments in dollars jumped to a new high in the U.S., while biotechnology remained the single hottest sector in 2020. . . . → Read More: 2020 Venture Funds Mixed, Biotech Keeps Sizzling

Covid-19 Antibody Developer Raises $483M in IPO

Wall Street sign

A biotechnology company developing therapeutic antibodies for Covid-19 infections is raising $483 million in its initial public offering of common stock. . . . → Read More: Covid-19 Antibody Developer Raises $483M in IPO